Advertisement

Exploiting Plug-and-Play Electrochemical Biosensors to Determine the Role of FGF19 in Sorafenib-Mediated Superoxide and Nitric Oxide Production in Hepatocellular Carcinoma Cells

  • Lixia Gao
  • Yong TengEmail author
Protocol
  • 4 Downloads
Part of the Methods in Molecular Biology book series (MIMB, volume 2138)

Abstract

Electrochemical biosensors provide rapid, selective, and sensitive diagnostic platforms for detecting and monitoring biochemical processes in living systems in vivo and in vitro, and have been widely applied in various fields of biology and medicine. Sorafenib is a multi-kinase inhibitor used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, the molecular basis for sorafenib resistance in HCC remains elusive. Recently, we developed new protocols for an electrochemical biosensor and applied these to monitor the levels of superoxide and nitric oxide produced in HCC cells, in the presence or absence of sorafenib. We also employed electrochemical biosensor to determine the release of profiles of superoxide and nitric oxide in sorafenib-treated HCC cells under the influence of fibroblast growth factor 19 expression levels. Here we present protocols to highlight the utility of electrochemical strategies in drug and gene studies.

Key words

Electrochemical biosensors Sorafenib FGF19 Superoxide Nitric oxide 

Notes

Acknowledgments

This research was supported by NIH grant R03DE028387 and R01DE028351 (to Y.T.).

References

  1. 1.
    Gao L, Teng Y (2016) Exploiting plug-and-play electrochemistry for drug discovery. Future Med Chem 8(5):567–577CrossRefGoogle Scholar
  2. 2.
    Teng Y, Zhao H, Gao L, Zhang W, Shull AY, Shay C (2017) FGF19 protects hepatocellular carcinoma cells against endoplasmic reticulum stress via activation of FGFR4-GSK3beta-Nrf2 signaling. Cancer Res 77(22):6215–6225CrossRefGoogle Scholar
  3. 3.
    Lang L, Shull AY, Teng Y (2019) Interrupting the FGF19-FGFR4 axis to therapeutically disrupt cancer progression. Curr Cancer Drug Targets 19(1):17–25CrossRefGoogle Scholar
  4. 4.
    Zhao X, Xu F, Dominguez NP, Xiong Y, Xiong Z, Peng H et al (2018) FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression. Mol Carcinog 57(11):1616–1625CrossRefGoogle Scholar
  5. 5.
    Lang L, Teng Y (2019) Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies. Cell 8(1):pii: E31.  https://doi.org/10.3390/cells8010031CrossRefGoogle Scholar
  6. 6.
    Gao L, Wang X, Tang Y, Huang S, Hu CA, Teng Y (2017) FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res 36(1):8.  https://doi.org/10.1186/s13046-016-0478-9CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gao L, Shay C, Lv F, Wang X, Teng Y (2018) Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells—a short report. Cell Oncol (Dordr) 41(1):85–91CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Department of Oral Biology and Diagnostic Sciences, Dental College of GeorgiaAugusta UniversityAugustaUSA
  2. 2.Chongqing University of Arts and SciencesChongqingPeople’s Republic of China
  3. 3.Georgia Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of GeorgiaAugusta UniversityAugustaUSA
  4. 4.Department of Medical Laboratory, Imaging and Radiologic Sciences, College of Allied HealthAugusta UniversityAugustaUSA

Personalised recommendations